These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20331626)

  • 1. Inhibition of ErbB2 by Herceptin reduces survivin expression via the ErbB2-beta-catenin/TCF4-survivin pathway in ErbB2-overexpressed breast cancer cells.
    Zhu H; Zhang G; Wang Y; Xu N; He S; Zhang W; Chen M; Liu M; Quan L; Bai J; Xu N
    Cancer Sci; 2010 May; 101(5):1156-62. PubMed ID: 20331626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of ErbB2 by herceptin reduces viability and survival, induces apoptosis and oxidative stress in Calu-3 cell line.
    Dogan I; Cumaoglu A; Aricioglu A; Ekmekci A
    Mol Cell Biochem; 2011 Jan; 347(1-2):41-51. PubMed ID: 20936496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance.
    Lu J; Tan M; Huang WC; Li P; Guo H; Tseng LM; Su XH; Yang WT; Treekitkarnmongkol W; Andreeff M; Symmans F; Yu D
    Clin Cancer Res; 2009 Feb; 15(4):1326-34. PubMed ID: 19228734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
    Xia W; Bisi J; Strum J; Liu L; Carrick K; Graham KM; Treece AL; Hardwicke MA; Dush M; Liao Q; Westlund RE; Zhao S; Bacus S; Spector NL
    Cancer Res; 2006 Feb; 66(3):1640-7. PubMed ID: 16452223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.
    Wang S; Huang J; Lyu H; Cai B; Yang X; Li F; Tan J; Edgerton SM; Thor AD; Lee CK; Liu B
    Breast Cancer Res; 2013; 15(5):R101. PubMed ID: 24168763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
    Asanuma H; Torigoe T; Kamiguchi K; Hirohashi Y; Ohmura T; Hirata K; Sato M; Sato N
    Cancer Res; 2005 Dec; 65(23):11018-25. PubMed ID: 16322251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
    Wang S; Huang X; Lee CK; Liu B
    Oncogene; 2010 Jul; 29(29):4225-36. PubMed ID: 20498641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2.
    Longva KE; Pedersen NM; Haslekås C; Stang E; Madshus IH
    Int J Cancer; 2005 Sep; 116(3):359-67. PubMed ID: 15800944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.
    Nagy P; Friedländer E; Tanner M; Kapanen AI; Carraway KL; Isola J; Jovin TM
    Cancer Res; 2005 Jan; 65(2):473-82. PubMed ID: 15695389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
    Chan CT; Metz MZ; Kane SE
    Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells.
    McKenzie T; Liu Y; Fanale M; Swisher SG; Chada S; Hunt KK
    Surgery; 2004 Aug; 136(2):437-42. PubMed ID: 15300212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/β-catenin/TCF-4 complex inhibition of c-MYC transcription.
    Antony L; van der Schoor F; Dalrymple SL; Isaacs JT
    Prostate; 2014 Aug; 74(11):1118-31. PubMed ID: 24913829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
    Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
    Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression.
    Henson ES; Hu X; Gibson SB
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):845-53. PubMed ID: 16467098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
    Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
    Huang X; Wang S; Lee CK; Yang X; Liu B
    Cancer Lett; 2011 Aug; 307(1):72-79. PubMed ID: 21497990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Indomethacin induces apoptosis through inhibition of survivin regulated by beta-catenin/TCF4 in human colorectal cancer cells].
    Zhu HX; Zhang G; Wang YH; Zhou CQ; Bai JF; Xu NZ
    Ai Zheng; 2004 Jul; 23(7):737-41. PubMed ID: 15248904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survivin expression promotes VEGF-induced tumor angiogenesis via PI3K/Akt enhanced β-catenin/Tcf-Lef dependent transcription.
    Fernández JG; Rodríguez DA; Valenzuela M; Calderon C; Urzúa U; Munroe D; Rosas C; Lemus D; Díaz N; Wright MC; Leyton L; Tapia JC; Quest AF
    Mol Cancer; 2014 Sep; 13():209. PubMed ID: 25204429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells.
    Wang LH; Chan JL; Li W
    Int J Cancer; 2007 Jul; 121(1):157-64. PubMed ID: 17304506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.